Patent No. US10801063 (titled "Methods and systems for detecting genetic variants") on Oct 14, 2019. The application was issued on Oct 13, 2020.
’063 is related to the field of genetic analysis, specifically the detection of rare genetic variants and copy number variations (CNV) in cell-free DNA (cfDNA) samples. In liquid biopsy applications, such as cancer monitoring, the ability to accurately quantify DNA fragments is often hampered by the loss of molecules during library preparation and sequencing, as well as errors introduced during PCR amplification.
The underlying idea behind ’063 is that the number of original DNA molecules in a sample can be more accurately estimated by tracking the recovery of complementary strands from individual double-stranded fragments. By using duplex tagging to distinguish the Watson and Crick strands, the system can identify which molecules were recovered as pairs, which were recovered as single strands, and—crucially—statistically infer the number of molecules that were entirely lost during the process.
The claims of ’063 focus on a method for classifying sequence data by non-uniquely tagging double-stranded cfDNA with a significant molar excess of barcoded adapters. The process involves grouping mapped sequencing reads into families based on their molecular barcodes and genomic start/stop positions to generate consensus sequences. These consensus sequences are then categorized as either paired (representing both strands of the original duplex) or unpaired (representing only one strand).
In practice, the invention utilizes a library of adapters where the number of unique barcodes is intentionally smaller than the number of DNA fragments, relying on the combination of the barcode and the fragment endpoints to uniquely identify parent molecules. This high-efficiency ligation ensures that a significant portion of the sample is tagged at both ends, allowing the bioinformatics pipeline to collapse redundant reads into high-fidelity consensus sequences while filtering out artifacts that appear on only one strand.
This approach differentiates itself from prior methods by moving beyond simple error correction to address the problem of stochastic sampling loss. By quantifying the ratio of paired to unpaired strands at specific genetic loci, the method corrects for local sequencing biases and missing data. This statistical inference provides a more robust foundation for detecting minute changes in copy number and identifying rare somatic mutations with a specificity exceeding 99.9%.
In the early 2010s when ’063 was filed, genomic analysis of heterogeneous samples was typically implemented using massively parallel sequencing of libraries where original nucleic acid fragments were converted into sequenceable forms via standard adapter ligation. At a time when systems commonly relied on bioinformatics to estimate copy number variation based primarily on the count of successfully sequenced reads, hardware and software constraints made it non-trivial to account for the stochastic loss of molecules during sample preparation. Engineering practices in this era generally accepted that a significant portion of the starting genetic material would remain unobserved, leading to inherent sensitivity limits when attempting to detect rare genetic variants or precise copy number changes in complex mixtures like cell-free DNA.
The disclosed invention represents a meaningful technical advancement through an architectural shift in how molecular redundancy and recovery are tracked to improve quantification accuracy. By utilizing a library of molecular barcodes to tag both strands of double-stranded DNA fragments in a single reaction, the system enables the differentiation between recovered pairs (both strands sequenced) and singlets (only one strand sequenced). This structural approach allows for the statistical inference of 'unseen' molecules that were converted but not sequenced, overcoming the technical constraint of sampling bias. The integration of this molecular counting method with high-fidelity amplification and consensus sequencing enables the detection of rare genetic variants with a specificity exceeding 99.9%, a capability enabled by correcting for the variable recovery rates across different genomic loci.
This patent contains a total of 28 claims, with claims 1 and 15 serving as the independent claims. The independent claims focus on methods for classifying consensus or unique sequencing reads derived from double-stranded cell-free DNA by utilizing high-molar excess adapter tagging with molecular barcodes to distinguish between paired Watson-Crick strands and unpaired single strands. The dependent claims serve to specify technical parameters such as sample types, DNA input amounts, barcode library sizes, ligation efficiencies, target cancer-related gene panels, and computational methods for quantifying both detected and undetected DNA molecules at specific genomic loci.
Definitions of key terms used in the patent claims.
US Latest litigation cases involving this patent.

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents